The final assessment report and related documents for the Other Technologies Collaborative Assessment 'Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)' are now available for access. The present assessment addressed
EUnetHTA is pleased to announce that the final project plan and related documents from external experts for the Other Technologies Collaborative Assessment OTCA23 "Biodegradable rectum spacers to reduce toxicity for prostate cancer'' are now available for access. The final assessment report
PTJA08 – “Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity” project plan now available.
The Final Project Plan of the assessment on siponimod is now available. The final assessment report will be published on 13th February, 2020. Please access the Final Project Plan at the following link: PTJA08 Final Project Plan
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the
The final assessment report and related documents concerning OTCA18, 'regional hyperthermia for high-risk soft tissue sarcoma treatment', are now available. The assessed technology is regional hyperthermia added to conventional therapies to treat high-risk soft tissue sarcoma. The objective of this rapid
Open Call for Patient Input for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum (NMOSD) disorders.
Patient group input requested for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum disorders. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have
EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA13 addresses ‘satralizumab indicated for the treatment of patients ≥12 years with neuromyelitis optica spectrum disorders (NMOSD)’, submitted by Roche. We are delighted that INFARMED, EUR (Erasmus
We are pleased to announce that the Final Assessment Report for PTJA07 is now available, with supporting documentation, for access. Please follow this link for full access.
We are pleased to publish the Autumn 2019 issue of EUnetHTA Magazine. Intended for improved accessibility on whichever device you use, this issue includes various contributions from the EUnetHTA member network, while updating information on EUnetHTA products and the state
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active